What this pack is
Entresto is the brand name in this record; sacubitril and valsartan is the generic name. Read both together with the dosage form (oral granules).
PACK CHECK · MARKET FIRST
EntrestoGeneric namesacubitril and valsartan
Mainland China pack-name cue诺欣妥®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The DailyMed label describes ENTRESTO as a combination of the neprilysin inhibitor sacubitril and the angiotensin II receptor blocker valsartan; it further states that sacubitril's active metabolite inhibits neprilysin while valsartan blocks the AT1 receptor. This explains label-described pharmacology, not an individual's cause of heart failure, suitability, tablet count, combination or switching plan.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 诺欣妥®
- International brand name
- Entresto
- Source-scoped market brand names
- 诺欣妥® · Mainland China (dated Novartis China public record)First-party brand history ↗A dated Novartis China public record maps Entresto® (诺欣妥®) to sacubitril/valsartan; later first-party material describes sacubitril/valsartan sodium tablets. This establishes a China trade-name and generic-name cue, not an exact Chinese package strength here. The U.S. ENTRESTO dossier's 24/26, 49/51 and 97/103 mg tablets and two SPRINKLE pellet products are U.S.-label identities and cannot be converted across markets from the names or a total milligram number.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- sacubitril and valsartan
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:诺欣妥®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
Tablet panels and ENTRESTO SPRINKLE pellet panels are different labelled product forms. A shared brand, ingredient or number never creates a self-directed tablet-to-pellet conversion, splitting, opening, combination or substitution plan.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
5 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v25; effective/updated 6 Jul 2026 and published 7 Jul 2026
Per tablet: sacubitril 24 mg + valsartan 26 mg; 60-tablet bottle
- Product code
- NDC 0078-0659-20
- Form and route
- ENTRESTO sacubitril/valsartan oral film-coated tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-21; actual marketing, stock and availability are not established.
- sacubitril
- 24 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- valsartan
- 26 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- Package
- 60 tablets per bottle
United States label · DailyMed SPL v25; effective/updated 6 Jul 2026 and published 7 Jul 2026
Per tablet: sacubitril 49 mg + valsartan 51 mg; 60-tablet bottle
- Product code
- NDC 0078-0777-20
- Form and route
- ENTRESTO sacubitril/valsartan oral film-coated tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-21; actual marketing, stock and availability are not established.
- sacubitril
- 49 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- valsartan
- 51 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- Package
- 60 tablets per bottle
United States label · DailyMed SPL v25; effective/updated 6 Jul 2026 and published 7 Jul 2026
Per tablet: sacubitril 97 mg + valsartan 103 mg; 60-tablet bottle
- Product code
- NDC 0078-0696-20
- Form and route
- ENTRESTO sacubitril/valsartan oral film-coated tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-21; actual marketing, stock and availability are not established.
- sacubitril
- 97 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- valsartan
- 103 mglabelled amount per tablet; not an individual's tablet count, conversion or adjustment rule
- Package
- 60 tablets per bottle
United States label · DailyMed SPL v25; effective/updated 6 Jul 2026 and published 7 Jul 2026
Pellets in each capsule: sacubitril 6 mg + valsartan 6 mg; 60-capsule bottle
- Product code
- NDC 0078-1231-20
- Form and route
- ENTRESTO SPRINKLE sacubitril/valsartan oral pellets in a capsule shell · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-21; actual marketing, stock and availability are not established.
- sacubitril
- 6 mglabelled amount in the pellets of each capsule; not an individual's capsule count, conversion or administration instruction
- valsartan
- 6 mglabelled amount in the pellets of each capsule; not an individual's capsule count, conversion or administration instruction
- Package
- 60 capsules per bottle
- Labelled appearance
- white capsule cap · capsule shell containing oral pellets · imprint 04Unscored in this labelled presentation
United States label · DailyMed SPL v25; effective/updated 6 Jul 2026 and published 7 Jul 2026
Pellets in each capsule: sacubitril 15 mg + valsartan 16 mg; 60-capsule bottle
- Product code
- NDC 0078-1238-20
- Form and route
- ENTRESTO SPRINKLE sacubitril/valsartan oral pellets in a capsule shell · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-21; actual marketing, stock and availability are not established.
- sacubitril
- 15 mglabelled amount in the pellets of each capsule; not an individual's capsule count, conversion or administration instruction
- valsartan
- 16 mglabelled amount in the pellets of each capsule; not an individual's capsule count, conversion or administration instruction
- Package
- 60 capsules per bottle
- Labelled appearance
- yellow capsule cap · capsule shell containing oral pellets · imprint 10Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ENTRESTO label reading: 24/26, 49/51 and 97/103 identify two ingredients in one product
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the U.S. DailyMed public label and Novartis package image to check ENTRESTO, sacubitril/valsartan, the two numbers per tablet, film-coated tablet, package and target market. It does not provide an individual's tablet count, combination, switching or symptom-management plan.
- 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg state the labelled amounts of two ingredients: sacubitril and valsartan. Neither one number, a total milligram number nor the number on another valsartan product is a basis for self-combining, halving or substituting.
- The U.S. label lists film-coated tablets separately from ENTRESTO SPRINKLE oral pellets. Pellet packaging states that the capsule shell is opened for administration and the pellets are not swallowed whole, chewed or crushed; that does not establish the same handling for the film-coated tablet. Any splitting, crushing, opening or dosage-form switch must be confirmed from the current label for the exact product and a pharmacist.
- The label identifies important checks involving ACE inhibitors, other ARBs, potassium supplements/salt substitutes, potassium-sparing diuretics, NSAIDs and lithium. With blood-pressure, heart-failure, diuretic, pain or supplement products, have a clinician or pharmacist review the complete medicine list and actual packs; do not self-add, stop or substitute based on similar names.
- The label contains explicit restrictions for switching with ACE inhibitors and for some prior reactions, as well as pregnancy-related warnings. This page does not turn those label requirements into an individual transition schedule or treatment decision; starting, stopping, switching, missed doses or any new concern must be addressed with the prescribing team, pharmacist and current target-market label.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): ENTRESTO sacubitril/valsartan tablets and oral pellets public label (Novartis, Jul 2026 version) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Entresto (sacubitril and valsartan). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Entresto is the brand in this record and sacubitril and valsartan is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How sacubitril/valsartan works: the label describes two simultaneous pharmacologic pathways
- “Two pathways” does not let a mechanism page choose a person's heart medicine, decide whether to add a medicine or self-combine ENTRESTO with an ACE inhibitor, ARB or another blood-pressure medicine. History, blood pressure, kidney function, tests, prior reactions and all medicines require professional review together.
- Valsartan in the combination shares an ingredient with single-ingredient valsartan products, but package numbers, mechanism or names do not establish self-interchangeability, catch-up use, alternation or co-use; the complete product, dosage form and current label must be checked separately.
- A mechanism page cannot determine the cause of dizziness, fainting, face or throat swelling, breathing difficulty, marked weakness or another symptom. With an acute or severe concern, prioritise local urgent medical support; do not self-continue, stop or change treatment from mechanism wording.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): ENTRESTO sacubitril/valsartan tablets and oral pellets public label (Novartis, Jul 2026 version) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Entrestosacubitril and valsartan
This page includes an exact current U.S. public-label package panel for Entresto, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 2015. This historical locator is not a conclusion about current approval, availability, holder or another market.
DailyMed: ENTRESTO public label archive ↗FDA label archive version
This page links the 2026-07 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
DailyMed: ENTRESTO public label archive ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 诺欣妥®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.